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ABSTRACT 23 
Purpose   24 
The epidemiology of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) 25 
is changing.  Temporal trends and differences between healthcare settings must be described to 26 
better predict future risk factors associated with this dangerous bacterial infection. 27 
 28 
Methods   29 
A national MRSA-infected cohort was identified from 2002 through 2009 in the Veterans Affairs 30 
Healthcare System of the United States: hospital (HOS), long-term care (LTC), and outpatient 31 
(OPT).  We analyzed within-setting time trends using generalized linear mixed models and 32 
between-setting differences with χ2 and Wilcoxon rank-sum tests. 33 
 34 
Results 35 
The incidence of S. aureus, methicillin-susceptible S. aureus, and MRSA infections increased 36 
significantly over time in all three settings based on modeled annual percent changes (p<0.001).  37 
MRSA incidence rates rose by 14%, 10%, and 37% per year in the HOS, LTC, and OPT settings 38 
respectively.  Among 56,345 MRSA-infected patients, comorbidity burden was highest among 39 
LTC inpatients (n=4,427) and lowest among outpatients (n=7,250), with an average absolute 40 
difference in specific comorbidities of +2% and -7% respectively compared to HOS inpatients 41 
(n=44,668).  Over time, there was a significant (p≤0.02) decrease in previous inpatient 42 
admissions and surgeries (all settings); diabetes with complications and surgical site infections 43 
(HOS, OPT); median length of stay and inpatient mortality (HOS, LTC).  Alternatively, obesity, 44 
chronic renal disease, and depression were more common between 2002 and 2009 (p≤0.02).   45 
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 46 
Conclusions   47 
Over the past eight years, we observed significant changes in the epidemiology of MRSA 48 
infections, including decreases in traditional MRSA risk factors, improvements in clinical 49 
outcomes, and increases in other patient characteristics that may affect risk.50 
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INTRODUCTION 51 
Over the past decade, substantial shifts in the molecular and clinical epidemiology of methicillin-52 
resistant Staphylococcus aureus (MRSA) infections have been reported [1-12].  Although MRSA 53 
infections were once predominantly hospital-acquired, this insidious pathogen has evolved and is 54 
now pervasive in communities across the United States (U.S.) [2-4].  Ensuing evidence has 55 
documented the rise in community-associated MRSA (CA-MRSA) and decline in invasive 56 
healthcare-associated MRSA (HA-MRSA), altering the distribution of attributed exposure and 57 
onset, strain characteristics, and predominant infection types [1-12].  However, in this era of 58 
epidemiologic change, knowledge of trends in patient characteristics is limited.  59 
 60 
We therefore sought to describe the underlying patient populations infected with MRSA from 61 
diverse healthcare settings of a single source population.  Our objectives were to quantify 62 
differences in patient demographics, comorbidities, clinical characteristics, and outcomes 63 
between healthcare settings and describe within-setting changes over time among hospital 64 
inpatients, long-term care inpatients, and outpatients in the national Veterans Affairs (VA) 65 
Healthcare System. 66 
 67 
METHODS 68 
Study Design and Population.  To describe the epidemiology of MRSA from January 1, 2002 69 
through December 31, 2009, we utilized national databases documenting care provided by the 70 
VA Healthcare System in the U.S. [13].  This retrospective, observational study identified 71 
MRSA-infected adult patients (≥18 years of age) from inpatient settings, consisting of hospital 72 
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admissions and long-term care facility admissions, and the outpatient setting.  This study was 73 
reviewed and approved by the Providence VA Medical Center Institutional Review Board.  74 
 75 
Incidence.  We assessed changes in MRSA incidence rates over time in the context of 76 
Staphylococcus aureus (S. aureus) infections.  Utilizing International Classification of Diseases, 77 
9th Revision (ICD-9) diagnosis codes, we identified S. aureus infections (ICD-9 038.11, 038.12, 78 
041.11, 041.12, 482.41, 482.42, V09.0), which were then categorized as methicillin-resistant 79 
(038.12, 041.12, 482.42, V09.0), or methicillin-susceptible (MSSA) based on the absence of a 80 
MRSA code [10].  The yearly incidence rate was calculated for each setting as the number of S. 81 
aureus, MSSA, and MRSA-related hospitalizations, long-term care admissions, or outpatient 82 
visits per 1,000 admissions or visits.  83 
 84 
Characteristics of MRSA-Infected Patients.  If patients had more than one MRSA-related 85 
admission or visit during the study period, the first encounter was selected for inclusion.  86 
Comorbidities were assessed from ICD-9 codes present during the MRSA-related admission/visit 87 
and any inpatient admission or visit in the previous year [14, 15].  Previous healthcare exposures, 88 
including inpatient admissions and surgeries, were captured in the year prior to the MRSA-89 
related admission/visit.  Infection type was categorized as bacteremia (ICD-9 038.11, 038.12, 90 
790.7), endocarditis (421.0), skin and soft tissue infection (ICD-9 681-682, 528.3), surgical site 91 
infection (998.5), osteomyelitis (730.0-730.2), and pneumonia (482-486) based on diagnoses 92 
present during the MRSA-related admission/visit [10, 15].  93 
 94 
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Statistical Analyses.  Differences in patient demographics, comorbidities, clinical 95 
characteristics, and outcomes between healthcare settings were analyzed with χ2 and Wilcoxon 96 
rank-sum tests for categorical and continuous variables respectively.  Within healthcare settings, 97 
we assessed the significance of temporal trends over the study years using generalized linear 98 
mixed models.  Due to changes in coding practices, sensitivity analyses were carried out 99 
excluding MRSA-infected patients diagnosed in 2009.  A p-value of <0.05 was considered 100 
statistically significant and all analyses were performed using SAS (SAS Institute Inc., Cary, 101 
NC, Version 9.2).  102 
 103 
RESULTS 104 
The incidence of S. aureus, MSSA, and MRSA infections increased significantly over time in all 105 
three settings based on modeled annual percent changes (p<0.001).  MRSA-related 106 
hospitalizations increased from 6.7 in 2002 to 15.9 in 2009, from 8.3 to 15.9 MRSA-related 107 
long-term care admissions, and from 0.01 to 0.08 MRSA-related outpatient clinic visits per 1,000 108 
admissions/visits (Fig 1).  MRSA incidence rates increased annually by 37% in the outpatient 109 
setting, 10% in long-term care, and 14% in hospitals.  Similarly, modeled MSSA incidence rates 110 
rose each year by 18% in the outpatient setting, 4% in long-term care, and 4% in hospitals.  We 111 
observed a 4% increase per year in the modeled incidence for S. aureus-related long-term care 112 
admissions, a 5% increase per year for hospital admissions, and a 21% increase per year for 113 
outpatient visits.  Sensitivity analyses demonstrated agreement, with the exception of non-114 
significant changes over time in MSSA incidence for the hospital and long-term care settings. 115 
 116 
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MRSA-infected long-term care inpatients (n=4,427) and outpatients (n=7,250) differed 117 
significantly (p≤0.035) from those hospitalized (n=44,668) on most characteristics assessed 118 
including demographics, comorbidities, previous healthcare exposures, and infection type (Table 119 
1).  Comorbidity burden was highest among MRSA-infected long-term care inpatients and 120 
lowest among outpatients, with an average absolute difference in specific comorbidities of +2% 121 
and -7% respectively compared to hospital inpatients.  Skin and soft tissue infections were the 122 
most commonly reported infection type in each healthcare setting (hospital 31%; long-term care 123 
18%; outpatient 23%), followed by pneumonia among inpatients (hospital 16%; long-term care 124 
16%) and osteomyelitis among outpatients (4%).  Endocarditis was reported in less than 1% of 125 
the MRSA-infected cohort and site of infection could not be determined from diagnosis codes in 126 
33% of patients (hospital 29%; long-term care 34%; outpatient 56%) [10, 15].  127 
 128 
Over time, the median Charlson Comorbidity Index changed significantly only among MRSA-129 
infected outpatients, decreasing from 3 in 2002 to 1 in 2009 (p=0.034).  Temporal trends within 130 
healthcare settings are presented in Table 2.  Significant decreases (p≤0.037) were observed in 131 
the modeled annual percent change of MRSA-infected patients with cerebrovascular disease 132 
(hospital 0.4%; long-term care 0.8%), diabetes with complications (hospital 0.4%; outpatient 133 
1.7%), dialysis (hospital 0.2%), and peripheral vascular disease (hospital 0.6%; outpatient 1.8%).  134 
Inpatient admissions and surgeries in the year prior to the MRSA-related admission/visit were 135 
significantly (p≤0.02) less common over time in all three settings (hospital 2.3% and 1.8%; long-136 
term care 0.9% and 1.3%; outpatient 3.4% and 2.4%).  Alternatively, in each healthcare setting, 137 
obesity and depression were more commonly reported from 2002 through 2009 in MRSA-138 
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infected patients (p≤0.02; hospital 1.4% and 1.2%; long-term care 1.2% and 1.7%; outpatient 139 
1.1% and 1.0%).  140 
 141 
Non-significant increases were observed in skin and soft tissue infections over the study period 142 
in all three settings.  Among MRSA-infected long-term care inpatients, infection type was 143 
relatively unchanged over time, except for a significant decrease (p<0.001) in pneumonia (1.5% 144 
modeled annual percent change).  Surgical site infections and osteomyelitis decreased 145 
significantly each year among hospital inpatients and outpatients (hospital 0.6% and 0.6%; 146 
outpatient 0.4% and 1.4%), while pneumonia increased 1.2% per year in the hospital setting.  147 
Among MRSA-infected inpatients, annualized decreases in median length of stay (hospital: 11 148 
days in 2002 to 6 days in 2009; long-term care: 52 days to 36 days) and inpatient mortality 149 
(hospital 0.9%; long-term care 1.7%) were significant (p≤0.01).  Changes in patient 150 
characteristics over time were similar in sensitivity analyses including data from 2002 through 151 
2008. 152 
 153 
DISCUSSION 154 
Our research uniquely assessed a comprehensive set of patient characteristics in three distinct 155 
clinical settings of a nationwide healthcare provider, with a well-defined source population, in 156 
the US.  From this large, national epidemiologic study, significant increases in MRSA incidence 157 
rates were discerned over the past eight years in the VA Healthcare System.  Our findings are 158 
similar to other national studies that have described rising MRSA incidence rates over the past 159 
decade among children and adults in the U.S. and Canada [6, 10, 16].  Unlike the diverse 160 
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healthcare settings we evaluated, these other studies were restricted to a single clinical setting, 161 
specifically hospitals [6, 10, 16].  162 
 163 
In both the hospital and long-term care settings, we observed non-significant declines in MRSA 164 
incidence rates between 2008 and 2009.  The interaction of several contributing factors may 165 
explain these reduced rates.  VA infection control policies targeting MRSA were enhanced under 166 
a nationwide directive, with full implementation in acute care facilities by December 31, 2007 167 
and expansion to other healthcare settings during 2009 [17].  The MRSA Prevention Initiative 168 
established active MRSA colonization surveillance and emphasizes contact precautions, hand 169 
hygiene, and cultural transformation as components of the overall MRSA prevention bundle, 170 
broadening infection control awareness through education [17, 18].   171 
 172 
Additionally, the introduction of new diagnosis codes for MRSA infections may have impacted 173 
coding practices.  Previously, MRSA could only be coded as a secondary diagnosis (V09.0), 174 
however primary ICD-9 codes for MRSA bacterial infection (041.12), MRSA septicemia 175 
(038.12), and MRSA pneumonia (482.42) were adopted in 2009.  Lastly, shifts in MRSA 176 
exposure and onset likely played a role in the recent decline, as CA-MRSA has gained a larger 177 
share of MRSA infections with subsequent reductions in HA-MRSA [2-5].  Active laboratory 178 
surveillance in 9 U.S. metropolitan areas revealed substantial yearly rate decreases in the 179 
incidence of invasive HA-MRSA infections from 2005 through 2008 [5].  We suspect the decline 180 
we observed in hospital MRSA incidence was considerably less than the reported HA-MRSA 181 
rate drop due to increases in invasive infections requiring inpatient care caused by CA-MRSA 182 
[1-5].   183 
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 184 
As expected, MRSA-infected long-term care inpatients had a higher comorbidity burden than 185 
hospital inpatients, and those hospitalized were in poorer health than outpatients.  In quantifying 186 
differences between healthcare settings, we found most comorbidities differed by several 187 
percentage points comparing hospitalized and long-term care inpatients, although this difference 188 
was more pronounced between outpatients and hospital inpatients.  189 
 190 
In regards to temporal trends among patients infected with MRSA, we observed significant 191 
declines in previously established MRSA risk factors, including diabetes with complications [19-192 
21], previous hospitalization [7, 20, 21], previous surgery [23], and dialysis [17, 22, 23].  Also 193 
significant over time were increases in obesity and depression.  Possible explanations for these 194 
increases include changes in the underlying patient population infected with MRSA in the VA 195 
Healthcare System, increased awareness and reporting, or the potential for these diseases to 196 
affect the risk of developing MRSA infections.  Overall, MRSA-infected patients appeared 197 
healthier over the study period in each of the three settings and clinical outcomes improved.  Our 198 
findings are consistent with rising rates of CA-MRSA and the distinct clinical epidemiology of 199 
CA-MRSA [2-5, 24].  200 
 201 
A considerable limitation in our study and several others [10, 25, 26], is the use of diagnosis 202 
codes to identify MRSA infections.  Due to the lack of microbiology research databases in U.S. 203 
healthcare systems, we are limited to diagnosis codes extracted from administrative data and 204 
electronic medical records [10, 13, 25, 26].  Until health informatics advancements are made to 205 
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extract and link such data, the only way to ascertain MRSA trends in large populations is with 206 
diagnosis codes.   207 
 208 
Similar to other research using diagnosis codes, we could only determine site of infection in two-209 
thirds of the cohort [10].  This may explain the absence of significant increases in MRSA skin 210 
and soft tissue infections over time.  Three of the MRSA diagnosis codes await validation as they 211 
were recently implemented (038.12, 041.12, 482.42).  The original MRSA diagnosis code 212 
(V09.0) has suboptimal sensitivity but a high positive predictive value, indicating 213 
underascertainment [10, 27, 28].  It is important to note that coding accuracy in VA databases is 214 
reportedly higher than other healthcare systems [29, 30].  Further, sensitivity has been found to 215 
increase with greater numbers of available diagnosis code entries, which is relatively high in the 216 
VA databases (13 entries per admission plus 5 per bed section, 10 per outpatient visit) [10, 13, 217 
27, 28].  The generalizability of the findings should be interpreted in the context of our source 218 
population, comprising 5.5 million patients treated annually by the VA Healthcare System, 219 
which is the largest integrated healthcare system in the country.   220 
 221 
In conclusion, MRSA incidence rates rose significantly over the past eight years in the VA 222 
Healthcare System.  We observed significant changes in the epidemiology of MRSA infections 223 
among hospital inpatients, long-term care inpatients, and outpatients from the same source 224 
population.  Over time, MRSA-infected patients appeared healthier, with fewer exposures to 225 
MRSA risk factors and improved clinical outcomes, suggesting CA-MRSA has gained 226 
considerable ground in the VA Healthcare System nationally.227 
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TABLES 
Table 1. Demographics, comorbidities, clinical characteristics, and outcomes by healthcare 
setting among MRSA-infected patients in the Veterans Affairs Healthcare System 
Covariates Hospital 
N = 44,668 
Long-term carea 
N = 4,427 
Outpatient 
clinica 
N = 7,250 
Median age, y (IQR) 63 (55-76) 68 (58-79) 60 (52-72) 
Male 43,337 (97.0) 4,305 (97.2)NS 6,711 (92.6) 
Race    
     White 33,445 (74.9) 3,462 (78.2) 5,206 (71.8) 
     African American 8,758 (19.6) 709 (16.0) 1,175 (16.2) 
Hispanic 2,417   (5.4) 187   (4.2) 301   (4.2) 
Region of facility    
     North 5,297 (11.9) 749 (16.9) 874 (12.0) 
     South 18,887 (42.3) 1,333 (30.1) 3,275 (45.2) 
     Midwest 9,537 (21.3) 1,309 (29.6) 1,462 (20.2) 
     West 10,947 (24.5) 1,036 (23.4) 1,639 (22.6) 
Admitted from home 38,155 (85.4) 1,471 (33.2) -- 
Median Charlson Comorbidity  
Index (IQR)  
3   (1-5) 3   (2-6) 1   (0-3) 
Comorbidities     
     Amputation 3,321   (7.4) 503 (11.4) 322   (4.4) 
     Cancer  9,943 (22.3) 1,110 (25.1) 1,056 (14.6) 
19 
 
     Cerebrovascular disease 7,441 (16.7) 960 (21.7) 631   (8.7) 
     Chronic renal disease 9,438 (21.1) 921 (20.8)NS 775 (10.7) 
     Chronic respiratory disease  15,925 (35.7) 1,688 (38.1) 1,683 (23.2) 
     Congestive heart failure 10,588 (23.7) 1,127 (25.5) 796 (11.0) 
     Depression 15,219 (34.1) 1,813 (41.0) 2,322 (32.0) 
     Diabetes  19,092 (42.7) 1,965 (44.4) 2,503 (34.5) 
     Diabetes with complications 9,238 (20.7) 1,032 (23.3) 1,010 (13.9) 
     Dialysis 1,517   (3.4) 142   (3.2)NS 87   (1.2) 
     Hypertension 31,925 (71.5) 3,304 (74.6) 4,474 (61.7) 
     Obesity 6,945 (15.5) 597 (13.5) 1,292 (17.8) 
     Paralysis 3,130   (7.0) 310   (7.0)NS 177   (2.4) 
     Peripheral vascular disease 9,320 (20.9) 1,136 (25.7) 919 (12.7) 
Previous healthcare exposures     
     Inpatient admission  27,408 (61.4) 3,630 (82.0) 2,211 (30.5) 
     Surgery  9,214 (20.6) 1,493 (33.7) 694   (9.6) 
Infection type     
     Bacteremia  6,650 (14.9) 591 (13.4) 191   (2.6) 
     Skin and soft tissue  13,892 (31.1) 805 (18.2) 1,656 (22.8) 
     Surgical site infection 2,803   (6.3) 343   (7.8) 186   (2.6) 
     Osteomyelitis  4,022   (9.0) 524 (11.8) 255   (3.5) 
     Pneumonia  7,149 (16.0) 696 (15.7)NS 141   (1.9) 
Outcomes    
     Inpatient mortality 2,701  (6.0) 1,006 (22.7) -- 
20 
 
     Follow-up MRSA admission 27,731 (62.1) 2,236 (50.5) 2,427 (33.5) 
     Median length of stay, d (IQR) 7 (4-15) 45 (21-105) -- 
 
Data are no. (%), unless otherwise indicated. MRSA, methicillin-resistant Staphylococcus 
aureus; IQR, interquartile range; NS, non-significant. 
a For all covariates, differed significantly compared to MRSA-infected hospitalized patients 
(p≤0.035), unless otherwise indicated (NS). Determined from χ2 or Wilcoxon Rank-Sum tests as 
appropriate. 
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Table 2. Temporal trends in demographics, comorbidities, clinical characteristics, and outcomes 
by healthcare setting among MRSA-infected patients in the Veterans Affairs Healthcare System 
Covariates Hospital 
N = 44,668 
 Long-term care 
N = 4,427 
 Outpatient clinic 
N = 7,250 
 2002 2009 ↓↑a  2002 2009 ↓↑a  2002 2009 ↓↑a 
Median age, y 67 63 NS  71 66 ↓  70 60 ↓ 
Male 97.7 96.4 ↓  97.6 96.2 NS  95.5 92.8 NS 
White 77.3 72.3 NS  81.0 75.0 ↓  78.3 71.3 ↓ 
Hispanic 5.4 5.4 NS  5.0 5.0 NS  3.0 4.4 NS 
Admitted from home 80.5 87.1 ↑  28.0 39.5 ↑  -- -- -- 
Median Charlson 
Comorbidity Index  
3 3 NS  3 4 NS  3 1 ↓ 
Comorbidities             
     Amputation 9.1 6.6 ↓  13.1 11.2 NS  12.6 3.4 ↓ 
     Cancer  24.3 22.4 NS  24.9 26.4 NS  20.2 13.8 NS 
     Cerebrovascular  
     disease 
19.7 16.7 ↓  24.5 20.5 ↓  11.1 8.0 NS 
     Chronic renal  
     disease 
19.1 23.3 ↑  13.3 26.7 ↑  10.6 11.1 NS 
     Chronic respiratory  
     disease  
37.9 33.7 NS  42.3 37.8 NS  33.3 22.8 NS 
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     Congestive heart  
     failure 
26.5 22.5 NS  27.3 26.9 NS  19.2 9.6 ↓ 
     Depression 28.8 37.1 ↑  36.1 45.9 ↑  26.8 35.2 ↑ 
     Diabetes  42.7 43.6 NS  43.2 47.2 NS  42.4 33.1 ↓ 
     Diabetes with  
     complications 
23.1 20.3 ↓  22.8 24.0 NS  22.7 12.6 ↓ 
     Dialysis 4.7 3.2 ↓  4.0 3.6 NS  1.5 1.1 NS 
     Hypertension 66.3 75.5 ↑  67.2 80.0 ↑  66.7 61.9 NS 
     Obesity 10.0 18.7 ↑  9.3 18.6 ↑  12.1 19.2 ↑ 
     Paralysis 9.0 6.3 ↓  9.3 6.7 NS  4.5 2.2 ↓ 
     Peripheral vascular  
     disease 
25.5 19.7 ↓  24.0 27.6 NS  23.7 10.7 ↓ 
Previous healthcare 
exposures 
           
     Inpatient admission  72.7 56.9 ↓  84.3 78.3 ↓  52.5 28.9 ↓ 
     Surgery  29.6 17.5 ↓  38.7 27.9 ↓  28.8 8.1 ↓ 
Infection type             
     Bacteremia  18.0 15.1 ↓  10.9 12.2 NS  2.5 3.0 NS 
     Skin and soft tissue  22.9 32.0 NS  15.0 16.2 NS  15.2 21.0 NS 
     Surgical site  
     infection 
8.7 5.5 ↓  8.8 7.2 NS  5.1 1.4 ↓ 
     Osteomyelitis  11.4 8.4 ↓  9.5 10.3 NS  12.6 2.2 ↓ 
     Pneumonia  19.8 11.3 ↓  20.7 9.0 ↓  2.0 2.2 NS 
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Outcomes            
     Inpatient mortality 9.9 4.1 ↓  28.7 17.4 ↓  -- -- -- 
     Follow-up MRSA  
     admission 
68.3 46.2 ↓  54.2 32.9 NS  62.1 21.9 ↓ 
     Median length of  
     stay, d 
11 6 ↓  52 36 ↓  -- -- -- 
 
Data are %, unless otherwise indicated. MRSA, methicillin-resistant Staphylococcus aureus; NS, 
non-significant. 
a Increased (↑) or decreased (↓) significantly over time (p≤0.037), unless otherwise indicated 
(NS), as determined from generalized linear mixed models. 
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FIGURE  
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Fig 1  Incidence of Staphylococcus aureus (S. aureus), methicillin-susceptible S. aureus 
(MSSA), and methicillin-resistant S. aureus (MRSA) hospital admissions, long-term care 
admissions, and outpatient clinic visits per 1,000 admissions or visits in the Veterans Affairs 
Healthcare System, 2002-2009 
 
 
 
 
  
 
 
 
 
